Drugs / CISH Inactivated TIL
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05566223 | Feb 2023 → Nov 2025 | large cell carcinoma, lung adenocarcinoma, squamous cell lung carcinoma | Intima Bioscience, Inc. | Withdrawn | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CISH Inactivated TIL | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05566223 ↗ |
| Action | Inhibit | “the intracellular immune checkpoint CISH has been inhibited” NCT05566223 ↗ |
| Modality | Cell therapy | “genetically-engineered Tumor Infiltrating Lymphocytes (TIL)” NCT05566223 ↗ |
| Route | Intravenous | “CISH inactivated TIL for infusion will be administered intravenously (IV)” NCT05566223 ↗ |
| Target | CISH | “the intracellular immune checkpoint CISH has been inhibited” NCT05566223 ↗ |